{
    "id": 29069,
    "fullName": "PRKAR1A - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PRKAR1A-ALK results from the fusion of PRKAR1A and ALK, which leads to autophosphorylation of Alk, increased Mapk activation, and transformation of cultured cells (PMID: 30002191). PRKAR1A-ALK fusion has been identified in inflammatory myofibroblastic tumors (PMID: 24875859, PMID: 24132104).",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                },
                {
                    "id": 13131,
                    "pubMedId": 24132104,
                    "title": "Tyrosine kinase gene rearrangements in epithelial malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24132104"
                },
                {
                    "id": 6382,
                    "pubMedId": 24875859,
                    "title": "Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24875859"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5573,
        "geneSymbol": "PRKAR1A",
        "terms": [
            "PRKAR1A",
            "ACRDYS1",
            "ADOHR",
            "CAR",
            "CNC",
            "CNC1",
            "PKR1",
            "PPNAD1",
            "PRKAR1",
            "TSE1"
        ]
    },
    "variant": "PRKAR1A - ALK",
    "createDate": "12/06/2018",
    "updateDate": "02/28/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15390,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PRKAR1A-ALK demonstrated decreased response to Alecensa (alectinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 30998,
                "profileName": "PRKAR1A - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15391,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PRKAR1A-ALK demonstrated decreased response to Ensartinib (X-396) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 30998,
                "profileName": "PRKAR1A - ALK"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15392,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PRKAR1A-ALK demonstrated decreased response to Lorbrena (lorlatinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 30998,
                "profileName": "PRKAR1A - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PRKAR1A-ALK demonstrated decreased response to Xalkori (crizotinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 30998,
                "profileName": "PRKAR1A - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30998,
            "profileName": "PRKAR1A - ALK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}